bridatec radiofarmaceutisk præparationssæt
ge healthcare srl. - mebrofenin, technetium (99m-tc) mebrofenin - radiofarmaceutisk præparationssæt
agros metrafenon suspensionskoncentrat
agros - metrafenon - suspensionskoncentrat - 300 g/l metrafenon
lfs metrafenon suspensionskoncentrat
lfs kemi - metrafenon - suspensionskoncentrat - 300 g/l metrafenon
tafinlar
novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuverende behandling af melanomadabrafenib i kombination med trametinib er angivet for den adjuverende behandling af voksne patienter med stadium iii melanom med en braf v600 mutation, efter komplet resektion. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
agro bizz metrafenon suspensionskoncentrat
lantmännen agro bizz a/s - metrafenon - suspensionskoncentrat - 300 g/l metrafenon
flexity suspensionskoncentrat
basf a/s - metrafenon - suspensionskoncentrat - 300 g/l metrafenon
lfs epoxiconazol - metrafenon suspensionskoncentrat
lfs kemi - epoxiconazol, metrafenon - suspensionskoncentrat - 83 g/l epoxiconazol ; 100 g/l metrafenon
ceando suspensionskoncentrat
basf a/s - epoxiconazol, metrafenon - suspensionskoncentrat - 83 g/l epoxiconazol ; 100 g/l metrafenon
agros metra epo suspensionskoncentrat
agros - epoxiconazol, metrafenon - suspensionskoncentrat - 83 g/l epoxiconazol ; 100 g/l metrafenon
mekinist
novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ikke-småcellet lungekræft (nsclc)trametinib i kombination med dabrafenib er indiceret til behandling af voksne patienter med avanceret ikke-småcellet lungekræft med en braf v600 mutation.